Ana Sandoval Leon, MD
Hematology & Oncology · Miami, FLNPI 1063709095
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,949 of the $51,252 with a category attached, or 93.6%. 13 manufacturers reported payments, led by Gilead at 49.9% of the total. Reporting peaked in 2024 at $22,176 and has fallen 66.4% since, to $7,443 in 2025.
Across 63 payments — averaging $813.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$26K
- AstraZeneca$8K
- Sanofi$6K
- Stemline Therapeutics Inc.$5K
- Lilly USA, LLC$2K
- Merck$2K
- plus $2K from 7 others
Across 154 payments — averaging $20,133 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2M
- Seagen Inc.$624K
- Merck$344K
- Pfizer$54K
- Genentech, Inc.$32K
- Novartis$13K
What the payments were for
- Consulting fees$47,94994%
- Travel & lodging$1,4383%
- Food & beverage$1,8544%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 15 | $25,588 |
| AstraZeneca | 8 | $8,282 |
| Sanofi | 4 | $5,598 |
| Stemline Therapeutics Inc. | 2 | $5,280 |
| Lilly USA, LLC | 13 | $2,243 |
| Merck | 4 | $1,893 |
| Daiichi Sankyo Inc. | 6 | $1,704 |
| Novartis | 5 | $266 |
| Astrazeneca UK Limited | 1 | $135 |
| Pfizer | 1 | $119 |
| Caris MPI, Inc. | 2 | $101 |
| Tempus AI, Inc | 1 | $25 |
| Puma Biotechnology, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,252 in reported general payments places this provider in the 85th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 37 | $568,243 |
| KisqaliRibociclib Succinate | 25 | $350,874 |
| OrserduElacestrant Hcl | 11 | $214,292 |
| Exemestane | 24 | $5,050 |
| Anastrozole | 210 | $4,243 |
| Tamoxifen Citrate | 31 | $771 |
| Letrozole | 20 | $575 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $210 |
| Ondansetron Hcl | 28 | $180 |
| Prochlorperazine Maleate | 13 | $148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $2,243 | $568,24337 claims |
| NovartisKisqali | $266 | $350,87425 claims |
| Stemline Therapeutics Inc.Orserdu | $5,280 | $214,29211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.